Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amgen reports second quarter financial results

August 2, 2023

Amgen announces 2023 third quarter dividend

July 31, 2023

Amgen announces webcast of 2023 second quarter financial results

July 30, 2023

FDA grants full approval for BLINCYTO® (blinatumomab) to treat minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia

June 20, 2023

Amgen to present at the goldman sachs 44th annual global healthcare conference

June 8, 2023

Amgen presents new LUMAKRAS® (sotorasib) CodeBreaK 200 CNS data at ASCO 2023

June 3, 2023

Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at ASCO 2023

May 31, 2023

Amgen presents new research on Otezla® (apremilast) in psoriatic arthritis at EULAR 2023

May 29, 2023

Amgen to present at the td cowen 4th annual oncology innovation summit

May 25, 2023

Amgen responds to FTC action re: proposed acquisition of Horizon Therapeutics

May 15, 2023

Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohn's disease

May 8, 2023

New data from Amgen's Prolia® (denosumab) demonstrates significant reduction in osteoporotic fracture risk compared to alendronate

May 7, 2023

Amgen to present at the 2023 bank of america merrill lynch global healthcare conference

May 2, 2023

Amgen reports first quarter financial results

April 26, 2023

Amgen announces webcast of 2023 first quarter financial results

April 20, 2023

Amgen wins patent appeal on Otezla® (apremilast)

April 18, 2023

Amgen to present at the 33rd annual oppenheimer healthcare conference

March 8, 2023

Amgen announces 2023 second quarter dividend

March 6, 2023

Amgen to present at the 43rd annual td cowen healthcare conference

March 2, 2023

Amgen to present new Repatha® (evolocumab) and olpasiran data at acc

February 28, 2023

Amgen announces cardiovascular study to evaluate Association between lipoprotein(a) and cardiovascular risk in African Americans

February 21, 2023

Amgen to present at the 2023 svb securities global biopharma conference

February 8, 2023

TEZSPIRE® approved for self-administration in the U.S. with a new pre-filled pen

February 1, 2023

AMJEVITA™ (adalimumab-atto), first biosimilar to Humira®, now available in the united states

January 30, 2023

Amgen reports fourth quarter and full year 2022 financial results

January 30, 2023

Amgen posts full transcript and audio replay of fourth quarter and full year 2022 earnings webcast

January 30, 2023

Amgen announces webcast of 2022 fourth quarter and full year financial results

January 25, 2023

Amgen and BioLabs LA at The Lundquist Institute announce Nammi Therapeutics to receive the third Amgen Golden Ticket

January 5, 2023

Amgen to present at the 41st annual j.p. morgan healthcare conference

January 3, 2023

BLINCYTO® (blinatumomab) added to consolidation chemotherapy significantly improves survival in adult patients with measurable residual disease-negative b-lineage acute lymphoblastic leukemia (B-ALL)

December 12, 2022

Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc

December 11, 2022

Amgen to host webcast investor call following announced acquisition of horizon therapeutics

December 11, 2022

Amgen announces 10% increase in 2023 first quarter dividend

December 11, 2022

Amgen presents new AMG 133 Phase 1 clinical data at WCIRDC 2022

November 30, 2022

Amgen to webcast investor call at wcirdc 2022

November 27, 2022

Amgen announces webcast of 2022 evercore isi healthcare conference

November 22, 2022

Amgen to present new research across serious inflammatory and Bone diseases at ACR 2022

November 6, 2022

Amgen presents new repatha® (evolocumab) data at aha 2022

November 6, 2022

Amgen presents new Phase 2 data that show olpasiran delivers significant reduction in lipoprotein(a) levels

November 5, 2022

Amgen announces webcast of 2022 credit suisse global healthcare conference

November 3, 2022

Amgen reports third quarter 2022 financial results

November 2, 2022

Amgen to webcast investor call at AHA 2022

November 1, 2022

Amgen announces webcast of 2022 third quarter financial results

October 30, 2022

Amgen announces 2022 fourth quarter dividend

October 27, 2022

Amgen successfully completes acquisition of ChemoCentryx

October 19, 2022

Amgen's annual trends report finds competition created by biosimilars contributed $21 billion in U.S. healthcare system savings

October 11, 2022

Amgen opens new state-of-the-art research and development laboratory site in San Francisco bay area

October 5, 2022

LUMAKRAS® (sotorasib) combined with Vectibix® (panitumumab) shows confirmed 30% objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer

September 11, 2022

Amgen announces webcast of 2022 bank of america merrill lynch global healthcare conference

September 11, 2022

LUMAKRAS®/LUMYKRAS® (sotorasib) demonstrates superior progression-free survival over docetaxel in first positive Phase 3 trial of a KRAS G12C inhibitor in non-small cell lung cancer

September 10, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.